Zhu reengineered the RSV F protein by changing a pair of molecules ... Sarah Auclair, Robyn L. Stanfield, Linling He, and Ian A. Wilson of Scripps. More information: Yi-Zong Lee et al, Rational ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. | Shionogi’s respiratory syncytial virus antiviral for adults has ...

First, they must enter the host cells, which RSV does using its fusion (F) protein. Vaccines induce antibodies that bind to pathogens. Neutralizing antibodies bind to crucial sites, such as part ...

S-337395 is an investigational oral antiviral candidate for RSV infection that inhibits the activity of the L protein, which is essential for virus replication. 1,2 Furthermore, this drug has received ...

The trimeric pre-fusion glycoprotein F is essential for accurately assessing the immunogenicity of RSV vaccines. We strictly adhere to regulations to provide high-quality, consistent, native ...